Drug survival rates and reasons for drug discontinuation in psoriasis

• DOI: 10.1111/ddg.13152
• Publication Date: 2016-11-23T16:53:47Z
• Authors: Tobias Arnold; Marthe‐Lisa Schaa...; Raphael Herr; Joachim E. Fischer; Sergij Goerdt; Wiebke K. Peitsch
• Keywords: Discontinuation; Ustekinumab; Acitretin

Moderate-to-severe psoriasis frequently requires long-term systemic therapy. Reflecting efficacy, safety, and treatment satisfaction, drug survival is an indicator of therapeutic success. The objective the present study was to assess rates reasons for discontinuation fumaric acid esters (FAE), methotrexate (MTX), acitretin (ACI), cyclosporine A (CyA), adalimumab (ADA), etanercept (ETA), infliximab (INF), ustekinumab (UST) in patients with moderate-to-severe psoriasis.We performed a retrospective analysis 373 who had received total 696 courses at German university hospital period 1/2003-5/2014.The crude probability highest UST, followed by ADA, ETA, INF, FAE, MTX, ACI, CyA. In multivariate regression using FAE as reference, hazard ratios (HR) were 0.14 (95 % confidence interval: 0.06-0.35) 0.43 (0.26-0.73) 2.11 (1.14-3.91) 3.26 (1.44-7.39) INF showed longer when combined MTX (HR 2.87, 1.21-6.81). Traditional antipsoriatic agents well most discontinued due adverse events; all other biologics, inefficacy respect cutaneous lesions.Drug should be integrated into decisions order provide optimal strategy.